Altamira Therapeutics Files Routine 6-K Report
Ticker: CYTOF · Form: 6-K · Filed: Apr 16, 2024 · CIK: 1601936
Sentiment: neutral
Topics: reporting, foreign-private-issuer, routine-filing
Related Tickers: ALTA
TL;DR
Altamira Therapeutics (ALTA) filed a 6-K, just a routine update, no major news.
AI Summary
Altamira Therapeutics Ltd. filed a Form 6-K on April 16, 2024, reporting as a foreign private issuer. The company, formerly known as Auris Medical Holding Ltd., is based in Hamilton, Bermuda. This filing does not contain specific financial details or operational updates but serves as a routine report.
Why It Matters
This filing indicates Altamira Therapeutics is meeting its reporting obligations as a foreign private issuer, which is standard for companies listed on US exchanges but incorporated elsewhere.
Risk Assessment
Risk Level: low — This is a routine filing with no new material information, financial data, or operational changes disclosed.
Key Numbers
- 001-36582 — SEC File Number (Identifies the company's filing with the SEC)
Key Players & Entities
- Altamira Therapeutics Ltd. (company) — Registrant
- Auris Medical Holding Ltd. (company) — Former company name
- 001-36582 (dollar_amount) — SEC File Number
- April 16, 2024 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC when they make public certain information in their home country or distribute it to their security holders.
When was Altamira Therapeutics Ltd. formerly known as Auris Medical Holding Ltd.?
The company was formerly known as Auris Medical Holding Ltd. with name changes occurring on March 18, 2019, March 14, 2019, and March 12, 2019.
Where is Altamira Therapeutics Ltd. headquartered?
Altamira Therapeutics Ltd.'s principal executive office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda.
Does this filing contain specific financial results for Altamira Therapeutics?
No, this Form 6-K filing does not appear to contain specific financial results or operational updates; it is a report of foreign private issuer information.
What is the SIC code for Altamira Therapeutics Ltd.?
The Standard Industrial Classification (SIC) code for Altamira Therapeutics Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 168 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-04-16 17:00:05
Filing Documents
- ea0203892-6k_altamira.htm (6-K) — 9KB
- ea020389201ex99-1_altamira.htm (EX-99.1) — 40KB
- ea020389201ex99-2_altamira.htm (EX-99.2) — 2KB
- ex99-1_001.jpg (GRAPHIC) — 8KB
- ex99-2_001.jpg (GRAPHIC) — 160KB
- ex99-2_002.jpg (GRAPHIC) — 133KB
- 0001213900-24-033500.txt ( ) — 466KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-36582 Altamira Therapeutics Ltd. (Exact name of registrant as specified in its charter) Clarendon House, 2 Church Street Hamilton HM 11, Bermuda (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Altamira Therapeutics Ltd. Date: April 16, 2024 By: /s/ Thomas Meyer Name: Thomas Meyer Title: Chief Executive Officer 1 EXHIBIT INDEX Exhibit Number Description 99.1 Notice to Shareholders dated May 16, 2024 99.2 Proxy Card for the Annual General Meeting of Shareholders 2